A Feasibility Study of Durvalumab + Tremelimumab in Resected Non-Small Cell Lung Cancer (NSCLC) Patients with Detectable Circulating Tumor DNA after Adjuvant Treatment
Study of Durvalumab + Tremelimumab in Non-Small Cell Lung Cancer Patients After Adjuvant Treatment
Sponsor: AstraZeneca
Enrolling: Male and Female Patients
IRB Number: AAAT0800
U.S. Govt. ID: NCT04625699
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this research study is to see how effective durvalumab andtremelimumab is in patients with early stage non-small cell lung cancer (NSCLC). A a special blood test will be done to see if subjects have circulating tumor DNA (ctDNA) in their blood. ctDNA are pieces of genetic material shed from the tumor cells that can be detected in the blood, which can suggests that there are left over cancer cells in the body or that the cancer is growing back. The purpose of this study is to evaluate the possibility and safety of giving investigational treatment with durvalumab and tremelimumab once the ctDNA is detected but before there is any evidence of cancer seen on imaging. Durvalumab and tremelimumab are a type of immunotherapy, which helps to stimulate the immune system.
This study is closed
Catherine Shu, MD
Do You Qualify?
Have you been diagnosed with non-small cell lung cancer (NSCLC)? Yes No
Do you have a life expectancy of at least 12 weeks? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator